TR200804209T1 - Hızlı salınım ve/veya kontrollü salınım özelliklerine sahip farmasötik dozaj biçimleri. - Google Patents

Hızlı salınım ve/veya kontrollü salınım özelliklerine sahip farmasötik dozaj biçimleri.

Info

Publication number
TR200804209T1
TR200804209T1 TR2008/04209T TR200804209T TR200804209T1 TR 200804209 T1 TR200804209 T1 TR 200804209T1 TR 2008/04209 T TR2008/04209 T TR 2008/04209T TR 200804209 T TR200804209 T TR 200804209T TR 200804209 T1 TR200804209 T1 TR 200804209T1
Authority
TR
Turkey
Prior art keywords
controlled release
dosage forms
pharmaceutical dosage
release
fast
Prior art date
Application number
TR2008/04209T
Other languages
English (en)
Inventor
Han Chien-Hsuan
Hsu Larry
F. Hsu Ann
Original Assignee
Impax Laboratories, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impax Laboratories, Inc filed Critical Impax Laboratories, Inc
Publication of TR200804209T1 publication Critical patent/TR200804209T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş genel olarak, bir emilim pencereli etken maddesi ve bir kontrollü salınım bileşeninden oluşan farmasötik dozaj biçimleriyle ilgili olup kontrollü salınım bileşeni enterik kaplamalı kontrollü salınım boncuklarını içermekte ve söz konusu enterik kaplamalı salınım boncukları pH'a duyarlı en az iki polimer tabakasına sahip bulunmaktadır. Kontrollü salınımlı dozaj biçimleri, emilim pencereli etken maddeleri için iyi bir biyolojik kullanılabilirlik düzeyini temin etmektedir.
TR2008/04209T 2005-09-30 2006-09-20 Hızlı salınım ve/veya kontrollü salınım özelliklerine sahip farmasötik dozaj biçimleri. TR200804209T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/239,249 US8007827B2 (en) 2004-04-02 2005-09-30 Pharmaceutical dosage forms having immediate release and/or controlled release properties

Publications (1)

Publication Number Publication Date
TR200804209T1 true TR200804209T1 (tr) 2008-08-21

Family

ID=37906654

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/04209T TR200804209T1 (tr) 2005-09-30 2006-09-20 Hızlı salınım ve/veya kontrollü salınım özelliklerine sahip farmasötik dozaj biçimleri.

Country Status (12)

Country Link
US (1) US8007827B2 (tr)
EP (1) EP1940361B1 (tr)
JP (1) JP5366549B2 (tr)
KR (1) KR20080059409A (tr)
CN (1) CN101312716A (tr)
AU (1) AU2006297477B2 (tr)
BR (1) BRPI0616703A2 (tr)
CA (1) CA2625481C (tr)
ES (1) ES2561585T3 (tr)
TR (1) TR200804209T1 (tr)
TW (1) TW200735899A (tr)
WO (1) WO2007040997A2 (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
WO2008058288A2 (en) * 2006-11-09 2008-05-15 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
GB2443738A (en) * 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
KR101752080B1 (ko) 2007-12-28 2017-06-28 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
JP5865904B2 (ja) 2010-06-16 2016-02-17 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド キサンチンオキシドレダクターゼ阻害剤またはキサンチンオキシダーゼ阻害剤の新規の調節放出剤形
US8685947B2 (en) * 2010-08-25 2014-04-01 Brown University Compositions and methods for loop diuretics with consistent bioavailability
CN102416170B (zh) * 2011-11-07 2013-08-07 重庆申高生化制药有限公司 多酶片的生产工艺
US9498441B2 (en) * 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
US20140106026A1 (en) * 2012-10-16 2014-04-17 Raphael Wald Article and method for treating, preventing and ameliorating alcohol-induced wernicke-korsakoff syndrome
JP2016516717A (ja) 2013-03-15 2016-06-09 シーダーズ−サイナイ メディカル センター メタン細菌に起因または関連する疾患および状態を診断、選択、および処置する方法
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
AU2014332024B2 (en) 2013-10-07 2019-09-26 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
KR101561345B1 (ko) * 2013-10-17 2015-10-16 대원제약주식회사 제어방출되는 프로피온산 계열의 약제학적 조성물
MX2017001971A (es) * 2014-08-13 2017-09-15 Cedars Sinai Medical Center Composiciones antimetanogenicas y sus usos.
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2016132233A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
KR20160105662A (ko) * 2015-02-27 2016-09-07 대원제약주식회사 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
EP3277274B1 (en) 2015-04-01 2024-06-12 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CA3013795A1 (en) * 2016-02-17 2017-08-24 Corr-Jensen Inc. Time release vitamins and minerals in edible oils
CN105748444B (zh) * 2016-03-30 2018-08-31 济南康和医药科技有限公司 一种双相释放的头孢妥仑匹酯制剂及其制备方法
CA3019482A1 (en) 2016-03-31 2017-10-05 Vhsquared Limited Compositions
CN108822816A (zh) * 2018-06-25 2018-11-16 中国石油集团渤海钻探工程有限公司 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法
US20220242945A1 (en) 2019-06-21 2022-08-04 Sorriso Pharmaceuticals, Inc. Polypeptides
US20230056445A1 (en) 2019-06-21 2023-02-23 Sorriso Pharmaceuticals, Inc. Polypeptides
CN113018273A (zh) * 2019-12-25 2021-06-25 上海宣泰医药科技股份有限公司 一种固体制剂及其制备方法和用途
EP3854385A1 (en) 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
CA3201057A1 (en) 2020-12-08 2022-06-16 Mark Christopher LAY Improvements to devices and methods for delivery of substances to animals
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
EP4340838A1 (en) * 2021-05-19 2024-03-27 Alberto Paz Orally administered compositions for cancer treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122039C (tr) * 1960-10-20
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
US4764380A (en) 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4780463A (en) * 1984-12-26 1988-10-25 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9308430D0 (en) 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
JPH072650A (ja) * 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
PL179910B1 (pl) 1994-05-06 2000-11-30 Pfizer Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
WO1996019974A1 (fr) 1994-12-27 1996-07-04 Kanebo, Ltd. Preparation a liberation prolongee
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
JP2001507359A (ja) 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
US7119189B2 (en) * 1997-03-19 2006-10-10 Novartis Ag Metabotropic GABA [B] receptors, receptor-specific ligands and their uses
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
AU6228799A (en) 1998-10-26 2000-05-15 Tanabe Seiyaku Co., Ltd. Sustained-release particles
HU230454B1 (hu) 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
AU3503300A (en) 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
FR2798289B1 (fr) 1999-09-15 2004-12-31 Cll Pharma Formes galeniques a delitement rapide en bouche et leur procede de preparation
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
SK6192003A3 (en) 2000-11-30 2004-07-07 Pfizer Prod Inc Combination of GABA agonists and sorbitol dehydrogenase inhibitors
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP3934383B2 (ja) * 2001-10-11 2007-06-20 アルフレッサファーマ株式会社 経口投与用製剤
US6781560B2 (en) 2002-01-30 2004-08-24 Harris Corporation Phased array antenna including archimedean spiral element array and related methods
US20030224045A1 (en) 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
WO2004062577A2 (en) * 2003-01-03 2004-07-29 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2007201808B8 (en) 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
WO2007149801A2 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient

Also Published As

Publication number Publication date
AU2006297477B2 (en) 2011-02-10
EP1940361A4 (en) 2011-03-02
CN101312716A (zh) 2008-11-26
CA2625481A1 (en) 2007-04-12
US8007827B2 (en) 2011-08-30
WO2007040997A3 (en) 2007-09-27
AU2006297477A1 (en) 2007-04-12
JP5366549B2 (ja) 2013-12-11
ES2561585T3 (es) 2016-02-29
BRPI0616703A2 (pt) 2016-09-06
KR20080059409A (ko) 2008-06-27
CA2625481C (en) 2012-01-03
US20060057197A1 (en) 2006-03-16
WO2007040997A2 (en) 2007-04-12
EP1940361B1 (en) 2015-11-04
TW200735899A (en) 2007-10-01
JP2009510065A (ja) 2009-03-12
EP1940361A2 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
TR200804209T1 (tr) Hızlı salınım ve/veya kontrollü salınım özelliklerine sahip farmasötik dozaj biçimleri.
WO2010080580A3 (en) Extended-release pharmaceutical formulations
WO2007052299A3 (en) Controlled release formulation
TR201818958T4 (tr) Bir kaplı ambalaj malzemesi üretmeye yönelik yöntem ve hidrofobobik bileşikler için en az bir bariyer tabakasına sahip Bir ambalaj malzemesi.
BRPI0612674A8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio, e, método para a profilaxia ou tratamento de hipertensão
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
NO2012017I1 (no) Benzimidazolderivat, fremgangsmåte for fremstilling derav, medikament inneholdende denne forbindelsen samt anvendelse av forbindelsen.
BRPI0410418A (pt) fenil quinolinas e seu uso como moduladores do receptor de estrogênio
WO2008150118A3 (en) Novel amide derivative for inhibiting the growth of cancer cells
BR122016030094B8 (pt) cápsula, tablete, grânulo ou grânulo fino, e, cápsula de liberação prolongada
WO2009129301A3 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
NO20091299L (no) Substituerte sulfonamidderivater
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
BRPI0822026A2 (pt) Prepação farmacêutica ou nutracêutica revestida com liberação acentuada de substância ativa no cólon.
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
ECSP088467A (es) Formulaciones de quinolinonas
CY1115955T1 (el) Ενα στερεο φαρμακευτικο σκευασμα
TR201906158T4 (tr) Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar.
WO2007080509A3 (en) Sustained release compositions of alfuzosin
ATE439361T1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
WO2008113916A9 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
MA29565B1 (fr) Combinaison de composes de pyrimidylaminobenzamide et imatinib permettant de traiter ou de prevenir les maladies proliferatives